Newer biomarkers such as cystatin c, neutrophil gelatinase-associated lipocalin, interleukin-18, or kidney injury molecule-1 are not only more sensitive, but can potentially elucidate different pathways involved in AKI development due to their different insults, given their different nature and origin [45]. This evidence concerns the gene LCN2 and acute kidney injury.